In some lymphomas, ibrutinib yields “almost unheard-of” survival ratesDecember 8, 2021DLBCLB Cell Lymphoma
Easing access to DLBCL treatments: Patient study reveals racial differencesNovember 17, 2021DLBCLB Cell Lymphoma
New trials in lymphoma and MM: Could your patient benefit?November 10, 2021DLBCLMantle Cell LymphomaB Cell Lymphoma
BTKi resistance: ‘Achilles’ heel’ in effective treatment of B-cell malignanciesOctober 15, 2021CLLB Cell Lymphoma
FDA grants zanubrutinib an accelerated approval in marginal zone lymphomaSeptember 16, 2021B Cell Lymphoma
High-dose methotrexate of no CNS benefit for patients with high-risk DLBCLMay 18, 2021B Cell LymphomaDLBCL
Pediatric cancer survivors at risk for opioid misuseMay 5, 2021ALLPatient & Survivor CareOpioid Resource CenterPediatricsAMLB Cell LymphomaCLL
